Retracted on Mar 12, 2026. Do not cite it as support.
Source: the publisher, via Crossref · checked Nov 3, 2026 · Read the notice
NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices
Hongqian Chu, Jian Zhao, Yongsheng Mi and 2 more
Nature Communications · 2019 · CC BY
doi:10.1038/s41467-019-10847-0
Abstract
Immunomodulatory therapies are becoming a paradigm-shifting treatment modality for cancer. Despite promising clinical results, cancer immunotherapy is accompanied with off-tumor toxicity and autoimmune adverse effects. Thus, the development of smarter systems to regulate immune responses with superior spatiotemporal precision and enhanced safety is urgently needed. Here we report an activatable engineered immunodevice that enables remote control over the antitumor immunity in vitro and in vivo with near-infrared (NIR) light. The immunodevice is composed of a rationally designed UV light-activatable immunostimulatory agent and upconversion nanoparticle, which acts as a transducer to shift the light sensitivity of the device to the NIR window. The controlled immune regulation allows the generation of effective immune response within tumor without disturbing immunity elsewhere in the body, thereby maintaining the antitumor efficacy while mitigating systemic toxicity. The present work illustrates the potential of the remote-controlled immunodevice for triggering of immunoactivity at the right time and site.
Full text
We don’t show the text of a retracted or withdrawn paper. The record stays, so citations to it can be checked.
Cited by papers we hold 4
- Smart/stimuli-responsive hydrogels: Cutting-edge platforms for tissue engineering and other biomedical applications · 2022No notice
- Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles · 2022No notice
- Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer · 2021No notice
- Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy · 2021No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.